Project Grant HT94252311016
Award Date
9/30/23
Completion Date
9/29/25
Dollars Obligated
$799K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60612, USA
Similar Awards
The University of Illinois was awarded a $293,978 Project Grant from the Department of Defense's Military Medical Research and Development (CFDA 12.420) program. The grant, titled "Cognition, Vascular Function, and Physical Activity in Multiple Sclerosis," will fund research investigating innovative approaches to understanding and managing neurological conditions relevant to military personnel and veterans. The project, with a performance period from November 1, 2024 to October 31,...
The University of Illinois received a $237,899 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "USING SENSORY PROCESSING TO IDENTIFY NEURAL CIRCUIT DEFICITS AND NOVEL TREATMENT STRATEGIES IN A RAT MODEL OF TSC". The research aims to transform healthcare for Service Members and the American public through innovative and impactful biomedical research. The award is for the project...
The University of Illinois was awarded a $1,499,728 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2023, will fund research to investigate a novel approach to reverse volumetric muscle loss following transfemoral amputations, with the goal of improving mobility and function. The research aims to transform health care for service members and the American public through innovative biomedical...
This Project Grant award of $639,600.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research by the University of Illinois to investigate the role of osteopontin-high macrophages in protecting against metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma. The research project will be conducted over a period of approximately 3 years, from August 1, 2024 to July 31, 2027. The University of...
This federal Project Grant award in the amount of $1,599,997.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award is for a clinical trial to research multiple sclerosis, with a performance period from September 1, 2024 to August 31, 2027. The University of Illinois, a major public research university, is the awardee and will serve as the primary research institution conducting this multi-year clinical trial....
This federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $1,602,572.00 in funding to the University of Illinois to support research on the role of the novel hexokinase HKDC1 in hepatocellular carcinoma. The award has a performance period from July 15, 2024 to July 14, 2027. The University of Illinois, a major public research university in Chicago, will conduct innovative scientific studies to advance...
The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
This Project Grant award of $999,996.00 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) is supporting research at the University of Illinois to investigate the mechanism governing the association between viral respiratory infection relapse and disease progression in persons with multiple sclerosis (MS). The research aims to transform health care for service members and the American public through innovative and impactful research, as...
The Defense Health Agency awarded a $3.755 million Project Grant to the University of Wisconsin-Madison through the Military Medical Research and Development program (CFDA 12.420) to investigate dual orexin antagonist treatment to prevent neurobehavioral sequelae of traumatic brain injury from April 1, 2023 to March 31, 2027. The Military Medical Research and Development program supports innovative medical research to improve warfighter health and transform public healthcare. Under this award,...
This federal Project Grant award was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) to the University of Illinois (Board of Trustees) for $905,863 starting on May 1, 2025. The grant funds a 4-year research project to investigate "NEUROACTIVE STEROID BIOSYNTHESIS AND DYNAMIC GABAA RECEPTOR RECONFIGURATION IN POSTPARTUM DEPRESSION." The project aims to advance scientific understanding and potential...